Myelodysplastic syndrome in a child with a history of medulloblastoma.
We present a case of myelodysplastic syndrome (MDS) following treatment for medulloblastoma. The tumor was diagnosed at 15 years of age and managed with surgery, craniospinal radiation and a triple-drug regimen [chloroethylnitrosourea (CCNU), vincristine (VCR), procarbazine]. Fifteen months after the completion of therapy, the patient developed MDS with monosomy 5 and monosomy 7 on chromosome analysis of bone marrow cells. Two weeks later, MDS evolved into acute myeloblastic leukemia (AML). Therapy-related MDS or AML may be a complication for patients with past brain tumors. Therefore, they should be carefully followed up by regular physical examinations and complete blood counts.
Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.
C
C
Akyüz
S
S
Emir
N
N
Güler
A
A
Tüker
M
M
Büyükpamukçu
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001856:Bone Marrow Examination; D002528:Cerebellar Neoplasms / Q000628:therapy*; D016371:Cranial Irradiation / Q000009:adverse effects; D017809:Fatal Outcome; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000209:etiology*; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D008527:Medulloblastoma / Q000628:therapy*; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000209:etiology*; D016609:Neoplasms, Second Primary / Q000209:etiology*; D011344:Procarbazine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine